Ethambutol Enantiomers - Chirality in Pharmacology

Introduction

Ethambutol is a first-line treatment for tuberculosis and is on the WHO list of essential medicines. It has two chiral centers, making stereochemistry doubly important for this drug.

Structure Comparison

Both enantiomers have the same ethylenediamine core connecting two hydroxyl-bearing branches. The two structures are mirror images of each other at both chiral centers simultaneously.

Chiral Center

Ethambutol has two chiral centers - one on each branch. In the therapeutic form, both are S-configured. In the toxic form, both are R-configured. Each chiral carbon bears an amino group, a hydroxymethyl group, an ethyl group, and a hydrogen.

Pharmacological Differences

The (S,S)-enantiomer inhibits arabinosyl transferase in Mycobacterium tuberculosis, disrupting cell wall synthesis. The (R,R)-enantiomer binds to proteins in the optic nerve, causing irreversible damage.

Clinical Impact

This is one of the most dramatic examples in pharmacology of enantiomers having opposite effects - one heals, the other harms. Ethambutol must be manufactured as the pure (S,S) form with strict quality control.

Key Takeaway

Ethambutol powerfully demonstrates that chirality is not just an academic concept - the wrong enantiomer can cause permanent disability. With two chiral centers, the stereochemical complexity is even greater.

Related Topics